Results 1 to 10 of about 308,973 (266)

Spatial and temporal genetic heterogeneity of epidermal growth factor receptor gene status in a patient with non-small cell lung cancer: a case report

open access: yesJournal of Medical Case Reports, 2011
Introduction To date, an epidermal growth factor receptor-activating mutation is recognized as a genetic hallmark that predicts a good response to treatment with epidermal growth factor receptor tyrosine kinase inhibitor.
Ogata Makoto   +3 more
doaj   +1 more source

A novel epidermal growth factor receptor inhibitor for treating lung cancer

open access: yesTumor Biology, 2017
To investigate the effects of a novel synthetic epidermal growth factor receptor inhibitor, COMPOUND7809, on the inhibition of lung cancer growth in vitro and the underlying mechanisms, we treated three lung tumor cell lines (A549, SK-LU-1, and NCI-H23 ...
Jiansheng Gao   +5 more
doaj   +1 more source

Radiotherapy and erlotinib combined: review of the preclinical and clinical evidence

open access: yesFrontiers in Oncology, 2012
Epidermal growth factor receptor is often overexpressed in tumors and has been associated with poor prognosis in some cancer types. The introduction of inhibitors of epidermal growth factor receptor, such as erlotinib and cetuximab, represents an ...
Vivek Krishan Mehta
doaj   +1 more source

Neural epidermal growth factor-like 1 expression predicts end-stage renal disease in phospholipase A2 receptor–negative membranous nephropathy: A retrospective cohort stratified by systemic lupus erythematosus

open access: yesJournal of International Medical Research
Background Neural epidermal growth factor-like 1 protein has emerged as a significant antigen in membranous nephropathy, an important cause of nephrotic syndrome in adults.
Qingqing Rao   +6 more
doaj   +1 more source

Evaluation of current methods to detect the mutations of epidermal growth factor receptor in non-small cell lung cancer patients

open access: yesMultidisciplinary Respiratory Medicine, 2012
Many different methods were developed to detect commonly known mutations and to screen new mutations of the epidermal growth factor receptor in non-small cell lung cancer patients.
Obradovic Jasmina, Jurisic Vladimir
doaj   +1 more source

Targeting colorectal cancer with anti-epidermal growth factor receptor antibodies: focus on panitumumab

open access: yesTherapeutics and Clinical Risk Management, 2008
Daanish Hoda1, George R Simon1, Christopher R Garrett1,21Division of Interdisciplinary Oncology, H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL, USA; 2Current affiliation: Department of Gastrointestinal Oncology, The University of Texas ...
Daanish Hoda   +2 more
doaj  

Potential Role of EGF and EGFR in Tongue Coating Formation

open access: yesWorld Journal of Traditional Chinese Medicine, 2016
Tongue coating, as a sensitive index of the physiological and pathological changes of human organs, is an important basis for the Traditional Chinese Medicine (TCM) syndrome differentiation and treatment.
Yi-Shuang Tang   +4 more
doaj   +1 more source

Cicatricial ectropion and madarosis associated with panitumumab treatment of metastatic colorectal cancer

open access: yesAmerican Journal of Ophthalmology Case Reports, 2020
Purpose: To report a case of cicatricial ectropion and madarosis with the use of anti-epidermal growth factor receptor medication panitumumab. Observations: An 82-year-old man with metastatic colorectal cancer presented with cicatricial ectropion and ...
Haoxing D. Jin, Nathan W. Blessing
doaj   +1 more source

HER2 Overexpression in Borderline and Malignant Ovarian Tumors: A Cross-sectional Study in an Iranian Population and Literature Review

open access: yesMiddle East Journal of Cancer, 2018
Background: Different studies have investigated the overexpression of human epidermal growth factor receptor 2 in ovarian cancers, in addition to the association between the level of its overexpression and tumor characteristics (tumor grade, subtype ...
Elham Asadinejad   +3 more
doaj  

An epidermal growth factor receptor compound mutation of L858R with S768I in advanced non-small-cell lung cancer: a case report

open access: yesJournal of Medical Case Reports
Background In the current treatment landscape for non-small cell lung cancers, epidermal growth factor receptor-tyrosine kinase inhibitors have emerged as a well-established treatment option for patients with advanced or metastatic disease.
Sara Boukansa   +11 more
doaj   +1 more source

Home - About - Disclaimer - Privacy